About
Joël oversees all operations at Ysios Capital, including management, strategy and standard operations. Joël serves on the board of TiGenix, AM-Pharma, MedLumics, and is chairman of the board at Inbiomotion. Formerly, he was board observer at Biovex (now AMGEN) and chairman of the board at Cellerix (now TiGenix). Previously, Joël co-founded GLYCART Biotechnology AG (Zürich, Switzerland) in March 2001 and was Chief Executive since inception. He raised €15 million in three rounds of financing for GLYCART before the company was sold to F.Hoffmann-La Roche Ltd in July 2005, a deal lauded as the deal of the year by the European Venture Capital magazine. As Chief Executive, he led all the fund-raising efforts, established a pan-European investment syndicate with leading venture capital firms and structured, negotiated and executed several key in- and out-licensing agreements with global pharmaceutical and biotechnology companies. Joël holds a master’s degree in Biochemistry, with a special
Position in the VCSift Database
- • 12 investors at Ysios Capital are tracked.
- • 2,531 investors hold the Managing Partner and Co - Founder role in VCSift. Joel Jean Mairet is one of them.
- • 820 investors are based in Barcelona, Catalonia, Spain.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Barcelona, Spain
Contact Information
Find more investors like Joel
Search Investors